Endologix to Participate in Two Investor Conferences in December

IRVINE, Calif., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, Vaseem Mahboob, Chief Financial Officer, and Bob Mitchell, President, are scheduled to participate at two investor conferences in December. The first conference is the 27th Annual Piper Jaffray Healthcare Conference in New York City.

Event: 27th Annual Piper Jaffray Healthcare Conference  
Date: Wednesday, December 2, 2015  
Time: 9:30 am ET  
Participant: John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer

The second conference is the Oppenheimer 26th Annual Healthcare Conference in New York City.

Event: Oppenheimer 26th Annual Healthcare Conference  
Date: Tuesday, December 8, 2015  
Time: 3:55 pm ET  
Participant: Bob Mitchell, President

An audio webcast of the Company's presentations at these conferences will be available by visiting the investor relations section of Endologix's website at www.endologix.com. A replay of the presentation will be available for 30 days.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S.

CONTACT: COMPANY CONTACT:

Endologix, Inc.  
John McDermott, CEO  
Vaseem Mahboob, CFO  
(949) 595-7200  
www.endologix.com

INVESTOR CONTACTS:  
The Ruth Group  
Nick Laudico (646) 536-7030  
Zack Kubow (646) 536-7020